|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altekruse SF, McGlynn KA, Dickie LA and
Kleiner DE: Hepatocellular carcinoma confirmation, treatment, and
survival in surveillance, epidemiology, and end results registries,
1992–2008. Hepatology. 55:476–482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
US National Library of Medicine.
ClinicalTrials.gov. http://www.Clinicaltrials.gov/ct2/Show/NCT025627552015
|
|
4
|
Cohen CJ, Shieh JT, Pickles RJ, Okegawa T,
Hsieh JT and Bergelson JM: The coxsackievirus and adenovirus
receptor is a transmembrane component of the tight junction. Proc
Natl Acad Sci USA. 98:15191–15196. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Walters RW, Freimuth P, Moninger TO,
Ganske I, Zabner J and Welsh MJ: Adenovirus fiber disrupts
CAR-mediated intercellular adhesion allowing virus escape. Cell.
110:789–799. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pandha HS, Stockwin LH, Eaton J, Clarke
IA, Dalgleish AG, Todryk SM and Blair GE: Coxsackie B and
adenovirus receptor, integrin and major histocompatibility complex
class I expression in human prostate cancer cell lines:
Implications for gene therapy strategies. Prostate Cancer Prostatic
Dis. 6:6–11. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kasuya H, Takeda S, Shimoyama S, Shikano
T, Nomura N, Kanazumi N, Nomoto S, Sugimoto H and Nakao A:
Oncolytic virus therapy-foreword. Curr Cancer Drug Targets.
7:123–125. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abdolazimi Y, Mojarrad M, Pedram M and
Modarressi MH: Analysis of the expression of coxsackievirus and
adenovirus receptor in five colon cancer cell lines. World J
Gastroenterol. 13:6365–6369. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Anders M, Vieth M, Rocken C, Röcken C,
Ebert M, Pross M, Gretschel S, Schlag PM, Wiedenmann B, Kemmner W
and Höcker M: Loss of the coxsackie and adenovirus receptor
contributes to gastric cancer progression. Br J Cancer.
100:352–359. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Thorne S, Hannock J, Francis J, Au
T, Reid T, Lemoine N, Kirn D and Halldén G: A novel assay to assess
primary human cancer infectibility by replication-selective
oncolytic adenoviruses. Clin Cancer Res. 11:351–360.
2005.PubMed/NCBI
|
|
11
|
Yamashita M, Ino A, Kawabata K, Sakurai F
and Mizuguchi H: Expression of coxsackie and adenovirus receptor
reduces the lung metastatic potential of murine tumor cells. Int J
Cancer. 121:1690–1696. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wunder T, Schmid K, Wicklein D, Groitl P,
Dobner T, Lange T, Anders M and Schumacher U: Expression of the
coxsackie adenovirus receptor in neuroendocrine lung cancers and
its implications for oncolytic adenoviral infection. Cancer Gene
Ther. 20:25–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wunder T, Schumacher U and Friedrich RE:
Coxsackie adenovirus receptor expression in carcinomas of the head
and neck. Anticancer Res. 32:1057–1062. 2012.PubMed/NCBI
|
|
14
|
Matsumoto K, Shariat SF, Ayala GE, Rauen
KA and Lerner SP: Loss of coxsackie and adenovirus receptor
expression is associated with features of aggressive bladder
cancer. Urology. 66:441–446. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dietel M, Häfner N, Jansen L, Dürst M and
Runnebaum IB: Novel splice variant CAR 4/6 of the coxsackie
adenovirus receptor is differentially expressed in cervical
carcinogenesis. J Mol Med (Berl). 89:621–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giaginis CT, Zarros AC, Papaefthymiou MA,
Papadopouli AE, Sfiniadakis IK and Theocharis SE: Coxsackievirus
and adenovirus receptor expression in human endometrial
adenocarcinoma: Possible clinical implications. World J Surg Oncol.
6:592008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martin TA, Watkins G and Jiang WG: The
Coxsackie-adenovirus receptor has elevated expression in human
breast cancer. Clin Exp Med. 5:122–128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martino TA, Petric M, Weingartl H,
Bergelson JM, Opavsky MA, Richardson CD, Modlin JF, Finberg RW,
Kain KC, Willis N, et al: The coxsackie-adenovirus receptor (CAR)
is used by reference strains and clinical isolates representing all
six serotypes of coxsackievirus group B and by swine vesicular
disease virus. Virology. 271:99–108. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Persson A, Fan X, Widegren B and Englund
E: Cell type- and region-dependent coxsackie adenovirus receptor
expression in the central nervous system. J Neurooncol. 78:1–6.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reimer D, Steppan I, Wiedemair A, Concin
N, Hofstetter G, Marth C, Müller-Holzner E and Zeimet AG: Soluble
isoforms but not the transmembrane form of coxsackie-adenovirus
receptor are of clinical relevance in epithelial ovarian cancer.
Int J Cancer. 120:2568–2575. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Wang S, Bao Y, Ni C, Guan N, Zhao
J, Salford LG, Widegren B and Fan X: Coxsackievirus and adenovirus
receptor expression in non-malignant lung tissues and clinical lung
cancers. J Mol Histol. 37:153–160. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang G, Zhang L, Zhu Q, Bai D, Zhang C
and Wang X: CD146 promotes metastasis and predicts poor prognosis
of hepatocellular carcinoma. J Exp Clin Cancer Res. 35:382016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stotz M, Gerger A, Haybaeck J, Kiesslich
T, Bullock MD and Pichler M: Molecular targeted therapies in
hepatocellular carcinoma: Past, present and future. Anticancer Res.
35:5737–5744. 2015.PubMed/NCBI
|
|
24
|
Wada Y, Takami Y, Tateishi M, Ryu T,
Mikagi K and Saitsu H: The efficacy of continued sorafenib
treatment after radiologic confirmation of progressive disease in
patients with advanced hepatocellular carcinoma. PLoS One.
11:e01464562016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bhayani NH, Jiang Y, Hamed O, Kimchi ET,
Staveley-O'Carroll KF and Gusani NJ: Advances in the pharmacologic
treatment of hepatocellular carcinoma. Curr Clin Pharmacol.
10:299–304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stecker K, Vieth M, Koschel A, Wiedenmann
B, Röcken C and Anders M: Impact of the coxsackievirus and
adenovirus receptor on the adenoma-carcinoma sequence of colon
cancer. Br J Cancer. 104:1426–1433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jebar AH, Errington-Mais F, Vile RG, Selby
PJ, Melcher AA and Griffin S: Progress in clinical oncolytic
virus-based therapy for hepatocellular carcinoma. J Gen Virol.
96:1533–1550. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang YG, Huang PP, Zhang R, Ma BY, Zhou XM
and Sun YF: Targeting adeno-associated virus and adenoviral gene
therapy for hepatocellular carcinoma. World J Gastroenterol.
22:326–337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bartlett DL, Liu Z, Sathaiah M,
Ravindranathan R, Guo Z, He Y and Guo ZS: Oncolytic viruses as
therapeutic cancer vaccines. Mol Cancer. 12:1032013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Larson C, Oronsky B, Scicinski J, Fanger
GR, Stirn M, Oronsky A and Reid TR: Going viral: A review of
replication-selective oncolytic adenoviruses. Oncotarget.
6:19976–19989. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pesonen S, Kangasniemi L and Hemminki A:
Oncolytic adenoviruses for the treatment of human cancer: Focus on
translational and clinical data. Mol Pharm. 8:12–28. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Choi JW, Lee JS, Kim SW and Yun CO:
Evolution of oncolytic adenovirus for cancer treatment. Adv Drug
Deliv Rev. 64:720–729. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wold WS and Toth K: Adenovirus vectors for
gene therapy, vaccination and cancer gene therapy. Curr Gene Ther.
13:421–433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma Y, Shurin GV, Peiyuan Z and Shurin MR:
Dendritic cells in the cancer microenvironment. J Cancer. 4:36–44.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gomez-Gutierrez JG, Nitz J, Sharma R,
Wechman SL, Riedinger E, Martinez-Jaramillo E, Sam Zhou H and
McMasters KM: Combined therapy of oncolytic adenovirus and
temozolomide enhances lung cancer virotherapy in vitro and in vivo.
Virology. 487:249–259. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saito Y, Sunamura M, Motoi F, Abe H, Egawa
S, Duda DG, Hoshida T, Fukuyama S, Hamada H and Matsuno S:
Oncolytic replication-competent adenovirus suppresses tumor
angiogenesis through preserved E1A region. Cancer Gene Ther.
13:242–252. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cai Y, Liu X, Huang W, Zhang K and Liu XY:
Synergistic antitumor effect of TRAIL and IL-24 with complete
eradication of hepatoma in the CTGVT-DG strategy. Acta Biochim
Biophys Sin (Shanghai). 44:535–543. 2012. View Article : Google Scholar : PubMed/NCBI
|
